Jan van de Winkel
CEO, Genmab
Van de Winkel co-founded Genmab in 1999 with the goal of unlocking the power of antibodies to make an impact on people’s lives. Through his leadership, Genmab’s innovations have led to six approved medicines to treat cancer and other serious diseases. Two of the seven bispecific (dual targeting) antibody medicines currently approved in the US and Europe incorporate Genmab’s DuoBody bispecific technology, a platform that Van de Winkel co-invented. Described as a visionary in the industry, Van de Winkel has authored more than 300 scientific publications and has been responsible for over 180 patents and patent applications. He is also passionate about young scientists and teaches an annual immunotherapy course at Utrecht University.
We asked…
What has been the biggest breakthrough in biopharma in recent years?
Bispecific (dual-targeting) antibodies have made significant advances as next-generation medicines in recent years, and I am extremely optimistic about the potential benefits of these targeted therapies for people with cancer and other serious illnesses. At Genmab, we strive to unlock the full potential of our “knock-your-socks-off” (KYSO) antibody medicines to make an impact on patients’ lives.
